Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2012 / Sayı: 1

Lymphatic targeting in Cancer Therapy

Kanser Tedavisinde Lenfatik Hedeflendirme

Pages
67–90
Publication Date
2012-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this context, basic information about cancer is given then, in the view of current studies, importance of targeting and advantages of lymphatic targeting in cancer therapy are explained.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cancer is a term used for diseases of uncontrollable self-division of abnormal cells, which are able to invade other tissues.
📊
Key Findings & Data:Radiotherapy, surgery and chemotherapy applications are in cancer treatment.
💡
Conclusion & Impact:In this context, basic information about cancer is given then, in the view of current studies, importance of targeting and advantages of lymphatic targeting in cancer therapy are explained.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kanser · Kanserde Hedeflendirme · Yeni İlaç Taşıyıcı Sistemler

Abstract

Cancer is a term used for diseases of uncontrollable self-division of abnormal cells, which are able to invade other tissues. Radiotherapy, surgery and chemotherapy applications are in cancer treatment. Chemotherapy can cause many side effects in cancer patients. Therefore, tumor tissue-specific drug carrier systems are needed. Drug toxicity is reduced as a consequence of preferential accummulation at target sites and lower concentration in healthy tissues. Examples of these systems are liposomes, micelles, micro-nanoparticulate systems. Cancer cells can spread to other parts of the body through the blood and lymphatic systems. Spread of cancer cells into surrounding tissues can be prevented by drug targeting to the lymphatic system. In this context, basic information about cancer is given then, in the view of current studies, importance of targeting and advantages of lymphatic targeting in cancer therapy are explained.

Özet

Kanser; kontrolsüz bölünen ve diğer dokulara yayılabilme özelliği olan anormal hücrelerin oluşturduğu hastalıklar için kullanılan bir terimdir. Kanser tedavisinde radyoterapi, ameliyat ve kemoterapi gibi yöntemler kullanılır. Kemoterapi; kanser hastalarında önemli yan etkilere neden olur. Bu nedenle; tümörlü dokuya özgü ilaç taşıyıcı sistemlere ihtiyaç duyulur. İlacın sağlıklı dokularda daha az birikmesinin ve tümörlü bölgede tercihen yoğunlaşmasının bir sonucu olarak ilaç toksisitesi azalır. Bu sistemlere örnek olarak; lipozomlar, miseller, mikro-nanopartiküler sistemler verilebilir. Kanser hücreleri vücudun diğer organlarına kan ve lenf yoluyla yayılırlar. İlacın lenfatik sisteme hedeflendirilmesinin bir sonucu olarak kanser hücrelerinin çevre dokulara yayılması önlenebilir. Bu derlemede öncelikle; kanser hakkında temel bilgiler verilmekte; daha sonra ise; bu konuda yapılmış güncel çalışmalar ve araştırmalar ışığında kanser tedavisinde ilacın hedeflendirilmesinin önemi ve lenfatik hedeflendirmeden nasıl yararlanılabileceği anlatılmaktadır.

🔖

Cite This Article

ÇEVİK, Ö., AYDIN, U., GÜRSOY, R. N. (2012). Lymphatic targeting in Cancer Therapy. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Sayı: 1, 67–90. https://ajindex.com/articles/762386

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. http://whqlibdoc.who.int/publications/2009/9789283204237_tur_p1-104.pdf http://www.kanser.gov.tr/folders/file/8iL-2006-SON.pdf
  2. Kutluk T., Kars A. (Editörler), Kanser Konusunda Genel Bilgiler, Ankara, Türk Kanser Araştırma ve Savaş Kurumu Yayınları, (1994), sayfa 26. www.cancervic.org.au/downloads/other_languages/turkish/Cancer_WhatIs.pdf http://www.cancer.gov/cancertopics/understandingcancer/cancergenomics/page49
  3. Vogelstein B., Kinzler K.W.: Cancer genes and the pathways they control, Nat Med, 10, 789 (2004). http://tr.wikipedia.org/wiki/P53 http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic
  4. Hart, I. R., “Metastasis”, Souhami R. L., Tannock, I., Hohenberger, P., Horiot, J.C. (Eds), Oxford Textbook of Oncology Second Edition,
  5. New York, Oxford University Press, (2002), cilt I, sayfa 103. http://en.wikipedia.org/wiki/Radiation_therapy
  6. Greish, K.: Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines, J Drug Target, 15, 457 (2007).
  7. Leaf, C.: Why we are losing the war on cancer (and how to win it), Fortune, 149, 84 (2004).
  8. Jain, R. K.: Molecular regulation of vessel maturation, Nat Med, 9, 685 (2003).
  9. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., McDonald, D. M.: Openings between defective endothelial cells explain tumor vessel leakiness, Am J Pathol, 156, 1363 (2000).
  10. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., Jain, R. K.: Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size, Cancer Res, 55, 3752 (1995).
  11. Wu, J., Akaike, T., Maeda, H.: Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase ınhibitor, and a nitric oxide scavenger, Cancer Res, 58 (1998).
  12. Kopecek, J., Kopeckova, P., Minko, T., Lu, Z.R., Peterson, C.M.: Water soluble polymers in tumor targeted delivery, J Control Release, 74, 147 (2001).
  13. Alberto, A., Gabizon, M. D.: Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy, Cancer Invest, 19, 424 (2001).
  14. Matsumura, Y., Maeda, H.: A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, 6387 (1986).
  15. Fukumura, D., Jain, R. K.: Tumor microvasculature and microenvironment: Targets for antiangiogenesis and normalization, Microvasc Res, 74, 72 (2